Interim report January - March, 2009

Interim report January - March, 2009

GROUP FINANCIAL DEVELOPMENT JANUARY - MARCH 
• Net sales totaled SEK 23.0 million
• Results from investing activities amounted to SEK 0.0 million
• Net income after tax was SEK 4.4 million
• Basic earnings per share was SEK 0.50 
• Equity per share was SEK 58.40 
• Equity/assets ratio was 70 percent

PARENT COMPANY FINANCIAL DEVELOPMENT JANUARY - MARCH 
• Results from investing activities was SEK 0.0 million (0.0) 
• Other revenue amounted to SEK 1.1 million (1.1) 
• Net loss after tax was SEK -3.3 million (- 3.5) 

KEY EVENTS IN THE FIRST QUARTER
• ONCOlog Medical receives FDA approval for PatLog™ and an order for TopLog©
• ONCOlog Medical receives SEK 8.0 million in a new share issue 
• Olerup SSP's HLA Typing kit is given the go ahead by the FDA for sales in the
U.S.
• Ortoviva's bone cement administrator is granted CE marking
• AbSorber's XM-ONE® study is published in prestigious medical journal
• AbSorber receives first orders in the U.S. for XM-ONE® 

LINKMED CEO INGEMAR LAGERLÖF COMMENTS ON THE FIRST QUARTER 2009:

“LinkMed got off to a strong start in 2009 and continues to demonstrate sound
profit development, generating operating profit of SEK 6.0 million in the first
quarter. Olerup SSP, the world-leading transplantation sector company we
acquired in 2008, contribu-ted an EBIT-result of SEK 12.8 million in the first
quarter. Moreover, LinkMed's other transplantation sector company, AbSorber,
received its first key orders from leading transplantation centers in the U.S.
during the first quarter. We continue to work on finding the best way to build a
larger joint company in the transplantation sector, which has all the
prerequisites of being a very profitable deal in the future.”


For more information please contact:
Ingemar Lagerlöf, CEO, cell +46 (0)70-873 2733 or email
ingemar.lagerlof@linkmed.se 
Okee Williams, Portfolio Manager, cell +46 (0)70- 600 5364 or email
okee.williams@linkmed.se



LinkMed develops life-science companies in collaboration with innovators and
other financiers. By contributing with management competence and capital,
LinkMed has created a portfolio of twelve companies, four in drug development
and biotechnology and eight in diagnostics and medical technology. The company's
principal owners are FastPartner, Koncentra Holding, and the founder Ingemar
Lagerlöf. The LinkMed share is listed on the NASDAQ OMX Nordic Exchange
Stockholm in the small-cap sector (ticker:LMED).